MedPath

GLP-1 Receptor Agonists Show Significant Weight Loss Benefits in Overweight and Obese Patients

3 years ago1 min read
Share
A systematic review and meta-analysis of 60 randomized clinical trials involving 24,969 patients has demonstrated the significant weight loss benefits of GLP-1 receptor agonists in overweight or obese individuals, both with and without type 2 diabetes mellitus (T2DM). The study, which included data from 22 trials with 17,183 patients, found that 50.2% of those treated with GLP-1 receptor agonists achieved ≥5% weight loss, and 17.5% achieved ≥10% weight loss, compared to 17.1% and 3.1% respectively in the placebo group.
  • Semaglutide SQ 2.4mg was identified as the most effective treatment, with an odds ratio (OR) of 8.32 for achieving ≥5% weight loss.
  • Semaglutide SQ <2.4mg and liraglutide SQ >1.8mg also showed significant efficacy, with ORs of 7.1 and 4.28 respectively.
  • Participants without T2DM achieved greater mean weight loss than those with T2DM, highlighting the differential efficacy of these treatments based on diabetes status.
  • Nausea was associated with greater mean weight loss, suggesting its potential as a clinical indicator of treatment efficacy.
The study underscores the importance of GLP-1 receptor agonists in the pharmacological management of overweight and obesity, offering a promising avenue for achieving significant weight loss and improving health outcomes in affected individuals.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

© Copyright 2025. All Rights Reserved by MedPath